First patient with colorectal cancer dosed in the Phase ll study of birinapant in combination with Keytruda®Read more
The transformation into a company focused on clinical development of pharmaceuticals has now been completed and Medivir gives a project updateRead more
Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignanciesRead more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.